Silo Pharma logo

Silo PharmaNASDAQ: SILO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 January 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$4.53 M
-81%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-76%vs. 3y high
31%vs. sector
-82%vs. 3y high
93%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:21:01 GMT
$1.01+$0.05(+5.20%)

Dividend

No data over the past 3 years
$18.00 K-$928.80 K

Analysts recommendations

Institutional Ownership

SILO Latest News

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
globenewswire.com31 October 2024 Sentiment: POSITIVE

The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. These tests were conducted under the Company's current development agreement with Sever Pharma Solutions.

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
globenewswire.com14 August 2024 Sentiment: POSITIVE

SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company's SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. In addition, Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies.

Why Is Silo Pharma (SILO) Stock Up 60% Today?
investorplace.com18 July 2024 Sentiment: POSITIVE

Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ: SILO ) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop an intranasal drug to address post-traumatic stress disorder (PTSD).

Why Is Silo Pharma (SILO) Stock Up 123% Today?
investorplace.com16 July 2024 Sentiment: POSITIVE

Silo Pharma (NASDAQ: SILO ) stock is rocketing higher on Tuesday after the developmental stage biopharmaceutical company secured a new global license. This license covers the development, manufacturing, and commercialization of its Alzheimer's drug SPC-14.

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
globenewswire.com07 June 2024 Sentiment: POSITIVE

Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the Company's SP-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. An ongoing pre-clinical research study of SP-26 is underway involving analytical testing services and small batch proof-of-concept extrusion trials for the ketamine hydrochloride (ketamine HCL) implants at 20% and 40% drug load.

Silo Pharma shares take off as anxiety and PTSD therapeutic candidate achieves milestone
Proactive Investors08 August 2023 Sentiment: POSITIVE

Silo Pharma shares rose on Tuesday after the development stage biopharmaceutical company announced it has advanced the formulation development of its therapeutic candidate SPC-15, achieving a liquid nasal formulation. This formulation of SPC-15, a targeted prophylactic treatment using ketamine compositions, is being investigated as a method of treatment and prevention of anxiety, post-traumatic stress disorder (PTSD) and other stress disorders.

What type of business is Silo Pharma?

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

What sector is Silo Pharma in?

Silo Pharma is in the Healthcare sector

What industry is Silo Pharma in?

Silo Pharma is in the Biotechnology industry

What country is Silo Pharma from?

Silo Pharma is headquartered in United States

When did Silo Pharma go public?

Silo Pharma initial public offering (IPO) was on 08 January 2021

What is Silo Pharma website?

https://silopharma.com

Is Silo Pharma in the S&P 500?

No, Silo Pharma is not included in the S&P 500 index

Is Silo Pharma in the NASDAQ 100?

No, Silo Pharma is not included in the NASDAQ 100 index

Is Silo Pharma in the Dow Jones?

No, Silo Pharma is not included in the Dow Jones index

When was Silo Pharma the previous earnings report?

No data

When does Silo Pharma earnings report?

Next earnings report date is not announced yet